For how we live.
A proposed rule would push several compliance dates under the 2024 trichloroethylene risk rule to 31 December 2027, giving processors and refrigerant makers more time to drop the solvent. Comments close 13 November.
ROAM/EORTC-1308, an independent phase 3 trial, randomised 157 patients after complete brain-tumour removal; adjuvant radiotherapy improved five-year disease-free survival, but the benefit's confidence interval was wide.
Cleared on 10 July under NDA 218579, the Provepharm agent fluoresces in near-infrared light to map vessels, perfusion and lymph nodes during surgery. Efficacy rests on studies of an earlier formulation.
Approved on 24 June under NDA 220436, the Avyxa Holdings product is a ready-to-infuse form of the NK-1 blocker fosaprepitant, cleared on studies of an earlier intravenous version of the drug.
In the 142,250-person NHS-Galleri trial, three rounds of screening did not reduce stage III or IV cancers versus usual care. A fall in stage IV cancers alone leaves the case unproven.
VITAL, with 25,871 adults, and D-Health, with 21,315, both tested vitamin D against placebo. Neither cut cancer incidence or cancer death — and one saw a signal pointing the wrong way.
Organic produce carries far fewer pesticide residues and modestly more of some antioxidants. But there is no strong evidence that eating organic makes you healthier, and the cancer signal is observational.
There are more than 18 million cancer survivors in the US, and finishing treatment is not the end of the health story. The strongest evidence for what helps is also the most ordinary.
A blood test after surgery can detect tumour DNA too faint to see on a scan. In one trial it let colon-cancer patients safely skip chemotherapy — but the evidence is still narrow.
Galleri-type tests can flag a cancer signal from a tube of blood and often guess its origin. But they miss most early-stage cancers, and no trial has yet shown they help people live longer.
The length of your chromosome caps is a noisy population-level marker, not a personal verdict — and genetically longer telomeres raise the risk of several cancers, not lower it.
Five-year follow-up of a Chinese randomised trial shows paclitaxel–cisplatin–capecitabine before chemoradiotherapy lifted failure-free survival from 63% to 78% in high-risk disease — at the cost of more toxicity.
A national survey finds treatment volumes above 2021 levels and linear accelerators replacing cobalt-60 units. Nearly every department still using cobalt says replacing the source is now unfeasible.
The committee that decides what Israel's national insurance covers added new cancer and depression drugs to the 2026 list — and turned down an early Alzheimer's treatment because of what it would have cost.
A large US analysis attributed 42 percent of cancer cases to modifiable risk factors. One factor dwarfs all the others, and it is not diet.
Stage describes how far a cancer has spread at diagnosis. It is not the same as grade, it is set once, and it drives both prognosis and treatment more than almost any other number.
Across 107 cohort studies and 4.8 million people, the protective effect of moderate drinking disappeared once the comparison group stopped including people who had quit because they were ill.
A 2025 US Surgeon General advisory put alcohol third among preventable causes of cancer. The global data show light drinking contributes too, not only heavy use.
In 390,124 US adults followed up to 27 years, daily multivitamin use showed no mortality benefit. Randomised trials within COSMOS found a real but modest effect on memory, and none on physical function.
A dose-response meta-analysis of 94 cohorts and more than 30 million people found the steepest part of the curve sits between zero and the recommended weekly dose, with small and uncertain gains above double it.
An inactive enzyme carried by an estimated 540 million people lets a carcinogen build up when they drink. In heavy-drinking carriers, oesophageal cancer risk runs many times higher.
Canada says two drinks a week. The US still says up to one or two a day. The gap is not a dispute about data — it is a dispute about where to draw a line on a continuous curve.
A comparison of 2020–2025 approvals finds 94 novel oncology drugs from the NMPA against 87 from the FDA, with China's volume overtaking from 2023. The speed and first-in-class figures run the other way.
In moderate-to-heavy drinkers who stopped for a month, insulin resistance fell by a quarter and two cancer-related growth factors dropped sharply — changes a matched control group did not show.
Three cohorts, 147,374 people, 30 years and 35,798 deaths. The dose-response curve flattened above 120 minutes per week, and the cancer signal appeared at the low end, not the high end.
A linked-registry cohort of New South Wales residents from 2001 to 2018 finds cancer risk in people with intellectual disability inverts with age — higher when young, lower after 50.
Of 1,363 evaluable patients matched to drugs by tumor genetics, 7% became exceptional responders. Activity across all 37 drugs was modest, and severe side effects hit over a quarter.
In 30,446 Malmö residents followed for decades, each step up in soot exposure was tied to 15% higher cardiovascular mortality — a stronger, steadier signal than total fine particles or traffic gases.
A December survey found getting stronger is the leading 2026 health goal. The best meta-analysis of muscle-strengthening and mortality finds a benefit that plateaus at around 30 to 60 minutes a week.
The Nature paper pairs mouse mechanism with retrospective human cohorts: vaccination within 100 days of starting a checkpoint inhibitor was associated with better survival. Retrospective is the load-bearing word.
Two Nature papers apply duplex sequencing with fewer than five errors per billion bases to cheek swabs and sperm — finding 46 genes under selection in mouth lining and a fatherhood risk that rises with age.